MD Anderson Center
Welcome,         Profile    Billing    Logout  
 33 Trials 
29 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tsimberidou, Apostolia
NCT03592264: A Phase I/II Study of OBI-3424 in Subjects With Advanced Solid Tumors

Terminated
1/2
68
US
OBI-3424
OBI Pharma, Inc
Solid Tumor, Pancreatic Adenocarcinoma
02/24
03/24
NCT04084366: Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors

Terminated
1/2
44
US
OBI-999
OBI Pharma, Inc
Locally Advanced Solid Tumor
10/23
10/23
NCT03195699: Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Active, not recruiting
1
60
US
TTI-101
Tvardi Therapeutics, Incorporated, M.D. Anderson Cancer Center
Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Hepatocellular Cancer, Colorectal Cancer, Gastric Adenocarcinoma, Melanoma, Advanced Cancer
12/24
12/24
C-800-01, NCT03860272: Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Recruiting
1
550
Europe, US
Botensilimab, AGEN1181, Anti-CTLA-4, Balstilimab, AGEN2034, Anti-PD-1
Agenus Inc.
Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer
 
 
ORB, NCT05947474: -011 In Patients With Advanced Solid Tumors

Recruiting
1
36
US
ORB-011
Orionis Biosciences Inc
Advanced Solid Cancer
03/25
06/25
IMPACT II, NCT02152254: Initiative for Molecular Profiling and Advanced Cancer Therapy

Active, not recruiting
N/A
1362
US
Targeted Therapy Based on Molecular Profiling, Standard-of-Care Therapy
M.D. Anderson Cancer Center, Tempus AI
Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
12/24
12/24
Yap, Timothy A
NCT05082025: Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

Active, not recruiting
2
7
US
Copanlisib, fulvestrant
M.D. Anderson Cancer Center, Bayer
Endometrial Cancer, Ovarian Cancer
10/26
10/26
NCT04020185: Safety and Efficacy Study of IMSA101 in Refractory Malignancies

Completed
1/2
40
US
IMSA101, Immune checkpoint inhibitor (ICI), Immuno-oncology (IO) therapy
ImmuneSensor Therapeutics Inc.
Solid Tumor, Adult
09/23
09/23
TRESR, NCT04497116 / 2020-000301-87: Study of RP-3500, Camonsertib, in Advanced Solid Tumors

Recruiting
1/2
285
Europe, Canada, US
RP-3500 (camonsertib), Talazoparib, Gemcitabine Injection
Repare Therapeutics, Roche Pharma AG
Advanced Solid Tumor
07/25
12/25
NCT03997968: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Active, not recruiting
1/2
170
US
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Cyteir Therapeutics, Inc.
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
07/24
12/24
NCT06077877: A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Recruiting
1/2
135
Canada, US
GSK4524101, Niraparib
GlaxoSmithKline
Neoplasms
12/27
11/29
NCT06065059: Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Terminated
1/2
7
US
TNG348, Olaparib, Lynparza
Tango Therapeutics, Inc.
Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer, BRCA1 Mutation, BRCA-Mutated Ovarian Carcinoma, BRCA-Associated Breast Carcinoma, HRD Positive Advanced Ovarian Cancer
05/24
05/24
PETRA, NCT04644068: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Calendar Jan 2024 - Dec 2024: Data from PETRA trial for advanced solid malignancies
Recruiting
1/2
804
Europe, Canada, Japan, US, RoW
AZD5305, Paclitaxel, Carboplatin, T- Dxd, Dato-DXd, Camizestrant
AstraZeneca
Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 5
12/26
12/26
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Recruiting
1
475
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
GlaxoSmithKline
Neoplasms
08/25
02/27
NCT04053673: Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors

Recruiting
1
130
Europe, US
RBN-2397
Ribon Therapeutics, Inc.
Solid Tumor, Adult
06/23
07/23
DRAGON, NCT04291079: SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
112
US, RoW
SRK-181, anti-PD-(L)1 antibody therapy
Scholar Rock, Inc.
Cancer
12/24
12/24
NCT06130254: Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Recruiting
1
52
US
Adagrasib, MRTX849, Olaparib, Lynparza™
M.D. Anderson Cancer Center, Mirati Therapeutics Inc.
Advanced Solid Tumor, Non-small Cell Lung Cancers
08/28
08/30
BGB-A317-15025-101, NCT04649385: BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

Recruiting
1
330
US, RoW
BGB-15025, Tislelizumab, BGB-A317
BeiGene
Advanced Solid Tumor
03/25
03/25
DDRiver Solid Tumours 301, NCT04170153: Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Active, not recruiting
1
204
Europe, Japan, US, RoW
M1774, Tuvusertib, Niraparib
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Metastatic or Locally Advanced Unresectable Solid Tumors
01/25
01/25
ACESOT-1051, NCT06260514: Study of APR-1051 in Patients With Advanced Solid Tumors

Recruiting
1
79
US
APR-1051
Aprea Therapeutics
Advanced Solid Tumor
06/27
06/28
AMBER, NCT02817633: A Study of TSR-022 in Participants With Advanced Solid Tumors

Hourglass Oct 2019 - Mar 2020 : From AMBER trial
Checkmark From AMBER trial at SITC 2018 [screenshot]
Nov 2018 - Nov 2018: From AMBER trial at SITC 2018 [screenshot]
Checkmark From AMBER trial in combination with TSR-022 at SITC 2018
Nov 2018 - Nov 2018: From AMBER trial in combination with TSR-022 at SITC 2018
Recruiting
1
447
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Tesaro, Inc.
Neoplasms
04/25
04/27
NCT04991480: A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Active, not recruiting
1
390
Europe, US
ART4215, Talazoparib, Talzenna, Niraparib, Zejula
Artios Pharma Ltd
Advanced Cancer, Metastatic Cancer, Breast Cancer
03/25
08/25
NCT05838768: Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

Recruiting
1
327
Europe, Japan, US, RoW
HRO761, tislelizumab, VDT482, irinotecan
Novartis Pharmaceuticals
MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
01/30
01/30
Petit, Robert
AOST-2121, NCT04974008: Osteosarcoma Maintenance Therapy With OST31-164

Completed
2
39
US
OST31-164
George Clinical Pty Ltd
Bone Cancer
09/23
09/23
ORB, NCT05947474: -011 In Patients With Advanced Solid Tumors

Recruiting
1
36
US
ORB-011
Orionis Biosciences Inc
Advanced Solid Cancer
03/25
06/25
Simeone, Diane
FAPI-46 PDAC, NCT05262855: Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma

Recruiting
2
60
US
[68Ga]FAPI-46
SOFIE
PDAC - Pancreatic Ductal Adenocarcinoma, FAP
12/24
12/24
EVEREST-1, NCT05736731: A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

Recruiting
1/2
160
US
A2B530, Tmod CAR T-cell Therapy, xT-Onco with HLA-LOH Assay
A2 Biotherapeutics Inc., Tempus AI
Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms, Pancreas Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent, Non-Small Cell Squamous Lung Cancer, NSCLC, NSCLC, Recurrent, Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, CRC, Colorectal Cancer Metastatic, Cancer
12/26
12/28
BASECAMP-1, NCT04981119: Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Recruiting
N/A
200
US
Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing
A2 Biotherapeutics Inc., Tempus AI
Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer, CRC, NSCLC, Pancreas Cancer, Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Mesothelioma, Malignant, Mesothelioma; Lung, Cancer
12/24
12/26
Bessmer, Chris
ELEVATE 2, NCT04712669 / 2020-004971-42: A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension

Completed
2
108
Europe, Canada, US, RoW
rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID, Placebo
Altavant Sciences GmbH
Pulmonary Arterial Hypertension
06/23
08/23
Hogg, Melissa
No trials found
Kanlikilicer, Pinar
No trials found
Radakovitz, Courtney
No trials found

Download Options